阿扎西提丁作为在儿科de novo急性髓性白血病的维持疗法
Chunping Wu1, Chunxia Cai1, Mei Li1
1Department of Paeditric Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou, China.
Frontiers in immunology
|December 22, 2025
概括
阿扎西提丁维持治疗并没有改善所有儿科急性髓性白血病 (AML) 患者的结果. 然而,它对核心结合因子AML (CBF-AML) 患有持续可测量的残留疾病 (MRD) 的患者显示出显著的益处.
科学领域:
- 儿科血液学 瘤学 儿科血液学
- 癌症治疗方法 癌症治疗方法
- 分子诊断学 分子诊断
背景情况:
- 儿科急性髓性白血病 (AML) 的复发是一个重大挑战,特别是对于无法接受造血干细胞移植 (HSCT) 的患者.
- 像阿扎西提丁这样的低甲基化剂正在被调查,以确定它们在儿科AML中向残留疾病的潜力.
- 阿扎西提丁作为新生儿AML的维持疗法的疗效和安全性需要进一步的临床验证.
研究的目的:
- 评估阿扎西提丁维护疗法的疗效和安全性,在儿科患者 de novo AML 在缓解.
- 在小儿AML患者中比较azacitidine维护和观察之间的结果.
- 确定小儿AML患者的特定亚组,他们可能受益于阿扎西提丁维护.
主要方法:
- 78名患有新发性AML缓解的儿科患者的回顾性队列研究.
- 患者被分配到阿扎西蒂丁维持 (6 个周期) 或观察.
- 使用多参数流细胞计和PCR对融合转录进行可测量的残留疾病 (MRD) 的纵向监测;评估无事件生存率 (EFS),总生存率 (OS),复发累积发生率 (CIR) 和安全性.
主要成果:
- 阿扎西提丁的维持显示了与整体队列中观察到的相似的EFS,OS和CIR.
- 在中等风险患者中观察到改善EFS和OS的趋势.
- 与观察相比,在持续性MRD (≥0.1%的融合转录) 的核心结合因子AML (CBF-AML) 患者中观察到显著优异的EFS和CIR,接受阿扎西提丁维持治疗 (EFS:100%与62.5%,p=0.048;CIR:0.0%与40.0%,p=0.042).
结论:
- 在特定的儿科AML亚组中,阿扎西提丁的维持可能会维持分子缓解,特别是CBF-AML患者患有不适用于HSCT的持续性MRD.
- 维护阿扎西提丁的潜在益处必须与其毒性概况相平衡,包括在40.7%的患者中观察到的2-4级骨髓抑制.
- 需要对更大规模的,前性,随机对照试验进行进一步的研究,以验证最佳剂量,时间安排和阿扎西提丁维持治疗的更广泛应用.
相关概念视频
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
194
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
194
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
174
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
174
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
229
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
229